相关实验视频

Updated: May 6, 2026

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

TROP-2不是黑色素瘤的治疗目标:一种形态学研究

Sonia Fantone¹, Daniela Marzioni², Elisa Molinelli³

¹Scientific Direction, IRCCS INRCA, 60124, Ancona, Italy.

Dermatology and therapy

|March 7, 2026

概括

热囊细胞表面抗原-2 (TROP-2) 在黑色素瘤中没有表达,这表明它不是这种皮肤癌的可行的治疗点. 需要进一步的研究来确定有效的黑色素瘤治疗方法.

科学领域:

在瘤学瘤学.
皮肤病学皮肤病学
分子生物学分子生物学

背景情况:

皮肤恶性黑色素瘤是一种致命的皮肤癌,其进展和复发率很高.
热囊细胞表面抗原-2 (TROP-2) 是一种参与细胞粘附的蛋白质,也是其他癌症中抗体-药物结合物的标.

研究的目的:

为了研究热细胞表面抗原-2 (TROP-2) 在黑色素瘤中的表达.
确定TROP-2是否可以成为黑色素瘤的潜在治疗点.

主要方法:

免疫组织化学和共聚焦显微镜用于分析TROP-2蛋白质表达.
研究人员检查了50种原发性黑色素瘤和10种黑色素细胞瘤.

主要成果:

在表皮黑色细胞和角质细胞的细胞膜上检测到TROP-2.
黑色细胞和黑色素瘤组织在任何阶段都没有显示可检测的TROP-2表达.

结论:

热囊细胞表面抗原-2 (TROP-2) 在黑色素瘤组织中没有表达.
根据这些发现,TROP-2不能被认为是黑色素瘤的治疗点.

关键词:

角质细胞 (keratinocytes) 是一种细胞.黑色素细胞黑色素细胞黑色素瘤是一种黑色素瘤.皮肤皮肤皮肤皮肤在TROP-2中.热囊细胞细胞表面抗原2 2

更多相关视频

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...